NCT03954405

Brief Summary

Prospective registry including incident patients and prevalent patients which pretends to identify clinical characteristics, treatment trends in-hospital and ten years follow-up outcome through major adverse cardiovascular events (MACE) in a China population with well characterized PAH.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2017

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

May 10, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 17, 2019

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

April 13, 2021

Status Verified

January 1, 2021

Enrollment Period

6.2 years

First QC Date

May 10, 2019

Last Update Submit

April 11, 2021

Conditions

Pulmonary Arterial Hypertension

Outcome Measures

Primary Outcomes (1)

  • survival

    To recruit a cohort of group 1 PAH cases. define the death as the primary outcome

    5 years

Secondary Outcomes (1)

  • clinical worsening

    5 years

Eligibility Criteria

Age1 Year - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with diagnosis of PAH from groups I

You may qualify if:

  • diagnosis of PAH (by RHC)

You may not qualify if:

  • Refusal to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wuhan Asian Heart Hospital

Wuhan, China

RECRUITING

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Condition Hierarchy (Ancestors)

Hypertension, PulmonaryLung DiseasesRespiratory Tract Diseases

Study Officials

  • Qiu Qiu

    Wuhan Asian Heart Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Zheng Xusn

CONTACT

+8618627885144soniazheng@outlook.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 10, 2019

First Posted

May 17, 2019

Study Start

November 1, 2017

Primary Completion

December 30, 2023

Study Completion

December 30, 2025

Last Updated

April 13, 2021

Record last verified: 2021-01

Locations

CN(1)